{
    "Clinical Trial ID": "NCT03273426",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Core Needle Biopsy",
        "  Ultrasound-guided core needle biopsy (14G, 5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.",
        "INTERVENTION 2: ",
        "  Vacuum-assisted Biopsy",
        "  Vacuum-assisted biopsy (10G, 5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patients",
        "  with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC)",
        "  who received NAC",
        "  with detectable lesion / clip marker on ultrasound",
        "  with cT1-T3 tumors",
        "  clinical and imaging complete or near-complete response on MRI",
        "  with informed consent",
        "Exclusion Criteria:",
        "  Multifocal cancer",
        "  Residual microcalcification",
        "  Contralateral breast cancer"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Negative Predictive Value",
        "  Percentage of participants with pathologic complete response (pCR) confirmed by surgical excision in patients predicted by biopsy to have pCR",
        "  Time frame: 2 weeks",
        "Results 1: ",
        "  Arm/Group Title: Core Needle Biopsy",
        "  Arm/Group Description: Ultrasound-guided core needle biopsy (14G,   5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.",
        "  Overall Number of Participants Analyzed: 17",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  88.2        (71.94 to 95.64)",
        "Results 2: ",
        "  Arm/Group Title: Vacuum-assisted Biopsy",
        "  Arm/Group Description: Vacuum-assisted biopsy (10G,   5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.",
        "  Overall Number of Participants Analyzed: 14",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  85.7        (64.37 to 95.22)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/20 (0.00%)",
        "Adverse Events 2:",
        "  Total: "
    ]
}